This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
11 Dec 2010

Genentech breathes new life into failed breast cancer drug

Genentech revealed that pertuzumab and Herceptin in addition to chemotherapy caused tumors to disappear in 45.8 percent of newly-diagnosed breast cancer patients, compared with 29 percent receiving only Herceptin and chemotherapy.

Genentech ($DNA) has found a new use for a failed drug. At the annual CTRC-AACR San Antonio Breast Cancer Symposium, the drugmaker revealed that pertuzumab and Herceptin in addition to chemotherapy caused tumors to disappear in 45.8 percent of newly-diagnosed breast cancer patients, compared with 29 percent receiving only Herceptin and chemotherapy. The trial included 419 women with early-stage, HER2-positive breast cancer--a genetic mutation that is present in about one quart of breast cancer cases.

Xconomy notes that pertuzumab was as good as gone in 2005. It was originally engineered to be a successor to Herceptin, but showed limited activity in Phase II trials of the treatment for ovarian, breast, and prostate tumors. But today's announcement indicates that pertuzumab real value as a combination therapy. Though patients experienced some notable side effects--including neutropenia, febrile neutropenia and severe diarrhea--Xconomy points out that the lack of cardiac events

Related News